anti-AchR | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

19,652 results for “anti-AchR”

Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis

Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment

FDA Approves Soliris for Refractory Myasthenia Gravis, First New Treatment in 60 Years

Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis

Eculizumab Shows Promise in Treating Thymoma-Associated Myasthenia Gravis

Zilbrysq Market Projected to Grow 21.64% Annually Through 2030 Following FDA Approval for Myasthenia Gravis

Ultomiris Shows Delayed but Significant Benefit in Generalized Myasthenia Gravis

NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment

FDA Approves UPLIZNA as First CD19-Targeted B Cell Therapy for Generalized Myasthenia Gravis

Page 1 of 587